• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

孕妇血清可溶性血管内皮生长因子受体 1 水平与胎盘部位滋养细胞肿瘤谱疾病的关系。

Relationship between maternal serum sFlt-1 level and placenta accreta spectrum disorders in the third trimester.

机构信息

Department of Gynecology and Obstetrics, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, China.

Center for Clinical Epidemiology, Peking University Third Hospital, Beijing, China.

出版信息

Arch Gynecol Obstet. 2024 Nov;310(5):2453-2459. doi: 10.1007/s00404-024-07734-5. Epub 2024 Sep 17.

DOI:10.1007/s00404-024-07734-5
PMID:39287684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485281/
Abstract

PURPOSE

This study aims to evaluate whether the third-trimester soluble fms-like tyrosine kinase-1 (sFlt-1) serum levels could be related to placenta accreta spectrum (PAS) disorders and the severity of postpartum blood loss.

METHODS

This was a nested case-control study which compared serum sFlt-1 level between gravid women with or without PAS disorders. Spearman correlation analysis was conducted to explore the relationship between sFlt-1 level and the volume of postpartum blood loss. Confounding factors were adjusted to avoid the impact on the results.

RESULTS

Sixty gravid women were enrolled: 36 women in the PAS group and 24 women in the non-PAS group. Women in the PAS group had a median sFlt-1 level of 9407.1 [2745.9-21,691.5] pg/ml, whereas women in the non-PAS group had a median sFlt-1 level of 25,779.2 [14317.1-35,626.7] pg/ml, (p < 0.001). The sFlt-1 level was negatively related to the volume of postpartum blood loss (r =  - 0.358, p = 0.041). After adjusting for maternal age and gestational age at blood taking, sFlt-1 level showed no significant relationship with PAS disorders (p = 0.245) and postpartum blood loss (p = 0.526).

CONCLUSION

Third-trimester sFlt-1 serum level is not independently associated with PAS disorders or postpartum blood loss after adjusting for confounding factors.

摘要

目的

本研究旨在评估第三 trimester 可溶性 fms 样酪氨酸激酶-1（sFlt-1）血清水平是否与胎盘部位滋养细胞肿瘤谱（PAS）疾病和产后出血量有关。

方法

这是一项巢式病例对照研究，比较了 PAS 疾病患者和无 PAS 疾病患者的血清 sFlt-1 水平。采用 Spearman 相关分析来探讨 sFlt-1 水平与产后出血量的关系。调整混杂因素以避免对结果的影响。

结果

共纳入 60 名孕妇：36 名孕妇为 PAS 组，24 名孕妇为非 PAS 组。PAS 组孕妇的 sFlt-1 中位数水平为 9407.1 [2745.9-21691.5] pg/ml，而非 PAS 组孕妇的 sFlt-1 中位数水平为 25779.2 [14317.1-35626.7] pg/ml，（p < 0.001）。sFlt-1 水平与产后出血量呈负相关（r = -0.358，p = 0.041）。调整母亲年龄和采血时的孕周后，sFlt-1 水平与 PAS 疾病（p = 0.245）和产后出血量（p = 0.526）均无显著相关性。

结论

在调整混杂因素后，第三 trimester sFlt-1 血清水平与 PAS 疾病或产后出血量无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/4d07b0140971/404_2024_7734_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/a5831acf172b/404_2024_7734_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/5e5fc56d6a5c/404_2024_7734_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/99067684299e/404_2024_7734_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/4d07b0140971/404_2024_7734_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/a5831acf172b/404_2024_7734_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/5e5fc56d6a5c/404_2024_7734_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/99067684299e/404_2024_7734_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3adb/11485281/4d07b0140971/404_2024_7734_Fig4_HTML.jpg

相似文献

1
Relationship between maternal serum sFlt-1 level and placenta accreta spectrum disorders in the third trimester.孕妇血清可溶性血管内皮生长因子受体 1 水平与胎盘部位滋养细胞肿瘤谱疾病的关系。
Arch Gynecol Obstet. 2024 Nov;310(5):2453-2459. doi: 10.1007/s00404-024-07734-5. Epub 2024 Sep 17.
2
Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.通过母体血浆 sFlt-1 和 PLGF 水平及其比值鉴别胎盘植入与前置胎盘。
Placenta. 2022 Jun 24;124:48-54. doi: 10.1016/j.placenta.2022.05.009. Epub 2022 May 14.
3
Association between placenta accreta spectrum and third-trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms-like tyrosine kinase-1: A meta-analysis.胎盘部位滋养细胞肿瘤谱与血管内皮生长因子、胎盘生长因子和可溶性 Fms 样酪氨酸激酶-1 血清水平在第三孕期的相关性：一项荟萃分析。
J Obstet Gynaecol Res. 2022 Sep;48(9):2363-2376. doi: 10.1111/jog.15330. Epub 2022 Jun 20.
4
Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder.可溶性 FMS 样酪氨酸激酶 1：在胎盘部位滋养细胞疾病谱中的作用。
F1000Res. 2021 Jul 21;10:618. doi: 10.12688/f1000research.54719.3. eCollection 2021.
5
Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.血清 VEGF 和 sFlt-1 在凶险性前置胎盘的临床价值。
Ann Med. 2021 Dec;53(1):2041-2049. doi: 10.1080/07853890.2021.1999492.
6
[Expression and significance of soluble fms-like tyrosine kinase 1 in preeclampsia placenta].可溶性fms样酪氨酸激酶1在子痫前期胎盘中的表达及意义
Zhonghua Fu Chan Ke Za Zhi. 2006 Aug;41(8):521-4.
7
The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders.血清 PLGF 和 sFLT-1 水平与胎盘组织表达水平及其与胎盘部位滋养细胞疾病 FIGO 分级的相关性。
J Matern Fetal Neonatal Med. 2023 Dec;36(1):2183744. doi: 10.1080/14767058.2023.2183744.
8
Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.胎盘生长因子和可溶性 fms 样酪氨酸激酶-1 可作为预测子痫前期的有用标志物，但不能作为预测小于胎龄儿的标志物：一项纵向研究。
Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):225-30. doi: 10.1016/j.ejogrb.2013.08.040. Epub 2013 Sep 4.
9
Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy.使用多种标志物的筛查模型用于低风险妊娠中晚发型子痫前期的早期检测。
BMC Pregnancy Childbirth. 2014 Jan 20;14:35. doi: 10.1186/1471-2393-14-35.
10
Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.血管内皮生长因子和胎盘生长因子对胎盘植入谱系疾病的预测价值。
J Obstet Gynaecol. 2022 Jul;42(5):900-905. doi: 10.1080/01443615.2021.1955337. Epub 2021 Sep 24.

本文引用的文献

1
The sonographic assessment to diagnose Placenta Accreta Spectrum disorders: "Riddled Cervix" and other signs.超声评估诊断胎盘植入谱系疾病：“宫颈筛孔状”及其他征象。
Arch Gynecol Obstet. 2024 Aug;310(2):1265-1266. doi: 10.1007/s00404-024-07575-2. Epub 2024 Jun 12.
2
Advances in pathogenesis of preeclampsia.子痫前期发病机制的进展
Arch Gynecol Obstet. 2024 May;309(5):1815-1823. doi: 10.1007/s00404-024-07393-6. Epub 2024 Feb 29.
3
Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum.胎盘植入谱系产前诊断中的潜在血清生物标志物
Front Med (Lausanne). 2022 May 30;9:860186. doi: 10.3389/fmed.2022.860186. eCollection 2022.
4
In reply: Is twin gestation an independent risk factor for placenta accreta spectrum?回复：双胎妊娠是胎盘植入谱系疾病的独立危险因素吗？
Am J Obstet Gynecol. 2022 Mar;226(3):447-448. doi: 10.1016/j.ajog.2021.10.024. Epub 2021 Oct 23.
5
Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States.胎盘植入谱系疾病的趋势、特征和结局：美国全国性研究。
Am J Obstet Gynecol. 2021 Nov;225(5):534.e1-534.e38. doi: 10.1016/j.ajog.2021.04.233. Epub 2021 Apr 21.
6
Serum miRNA biomarker discovery for placenta accreta spectrum.用于胎盘植入谱系的血清 miRNA 生物标志物发现。
Placenta. 2020 Nov;101:215-220. doi: 10.1016/j.placenta.2020.09.068. Epub 2020 Sep 29.
7
The diagnostic value of angiogenic and antiangiogenic factors in differential diagnosis of preeclampsia.血管生成和抗血管生成因子在子痫前期鉴别诊断中的诊断价值。
Am J Obstet Gynecol. 2022 Feb;226(2S):S1048-S1058. doi: 10.1016/j.ajog.2020.09.046. Epub 2020 Sep 28.
8
First trimester serum PIGF is associated with placenta accreta.早孕期血清 PIGF 与胎盘植入有关。
Placenta. 2020 Nov;101:39-44. doi: 10.1016/j.placenta.2020.08.023. Epub 2020 Sep 3.
9
FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders.FIGO 分类用于胎盘部位滋养细胞肿瘤的临床诊断。
Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761.
10
The Placenta Accreta Spectrum: Epidemiology and Risk Factors.胎盘植入谱系疾病：流行病学与危险因素
Clin Obstet Gynecol. 2018 Dec;61(4):733-742. doi: 10.1097/GRF.0000000000000391.